Sanofi Consumer Healthcare India Ltd

Sanofi Consumer Healthcare India Ltd maintains a strong liquidity position, with a current ratio of 3.85 and cash and equivalents amounting to INR 3.75 billion, which significantly exceeds its total liabilities of INR 1.63 billion. The company's liquidity is further supported by a free cash flow of INR 1.18 billion, indicating robust cash generation from operations. In terms of profitability, the company demonstrates a return on equity (ROE) of 62.53% and a return on assets (ROA) of 43.89%, both of which are well above the typical thresholds for the pharmaceutical industry. These figures suggest that the company is effectively utilizing its equity and asset base to generate returns. The company's revenue is primarily concentrated in the Indian market, with no disclosed international operations. This geographic concentration may expose the company to local regulatory and economic risks, although it also allows for focused market penetration and brand strength. Looking ahead, the company is expected to maintain a stable growth trajectory, supported by its strong cash flow and low debt levels. While no specific revenue growth percentages are provided, the company's operating cash flow of INR 1.75 billion and capital expenditure of INR 76 million suggest a conservative approach to reinvestment and expansion. The company's risk profile is characterized by low liquidity and dilution risks. There are no immediate filing-based liquidity or dilution flags, and the debt-to-equity ratio of 0.06 indicates a conservative capital structure with minimal leverage. Recent events and filings do not indicate any significant changes in the company's operations or financial strategy. The company's strong buy recommendation from analysts, with a mean price target of INR 5,855, suggests positive sentiment among market participants.